Laurus Labs Limited (BOM:540222)
1,004.95
+16.20 (1.64%)
At close: Jan 22, 2026
Laurus Labs Revenue
Laurus Labs had revenue of 17.84B INR in the quarter ending December 31, 2025, with 26.08% growth. This brings the company's revenue in the last twelve months to 67.48B, up 27.97% year-over-year. In the fiscal year ending March 31, 2025, Laurus Labs had annual revenue of 55.54B with 10.18% growth.
Revenue (ttm)
67.48B
Revenue Growth
+27.97%
P/S Ratio
8.13
Revenue / Employee
10.94M
Employees
6,167
Market Cap
548.71B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 55.54B | 5.13B | 10.18% |
| Mar 31, 2024 | 50.41B | -10.00B | -16.55% |
| Mar 31, 2023 | 60.41B | 11.05B | 22.39% |
| Mar 31, 2022 | 49.36B | 1.22B | 2.54% |
| Mar 31, 2021 | 48.14B | 19.82B | 69.99% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IOL Chemicals and Pharmaceuticals | 21.70B |
| Neuland Laboratories | 15.33B |
| Shilpa Medicare | 13.43B |
| Bajaj HealthCare | 6.11B |
| Sudeep Pharma | 5.61B |
| NGL Fine-Chem | 4.08B |
| Gujarat Themis Biosyn | 1.55B |
| Anlon Healthcare | 1.44B |